Spray Dried Dispersion Technology

Increasingly utilized for dry powder inhaler (DPI) application

The majority of today’s drug candidates have low aqueous solubility (BCS II) and require an enabling technology to enhance oral bioavailability. Amorphous solid dispersion approaches utilizing spray-dried dispersion (SDD) technology offer a proven and highly flexible approach to significantly improve the bioavailability of promising BCS ll compounds. Spray drying is also increasingly utilized for dry powder inhaler (DPI) applications, providing particle engineered formulations in the required particle size distribution to meet target product profiles.

Amorphous solid dispersion using spray-dried dispersions

With our integrated product development approach we can manufacture SDD formulations for all stages of development from preclinical and first-in-human to late-stage development and commercial production. Drug product intermediates based on SDD technology can be formulated into capsules, tablets and other solid dosage forms.

Contact us

SDD technology has been proven in thousands of compounds to result in significantly improved bioavailability, typically from three to 15-fold.

Design: the first step is understanding your problem statement and clearly defining the target product profile (TPP).

Develop: starting from the design and TPP, a team of experienced scientists and engineers develop the product using a proven roadmap approach. Generally, the formulations developed are “phase appropriate” to match the current development phase of the drug candidate.

Manufacture: we have a full range of pharmaceutical spray dryers, based on proprietary designs, to support early feasibility assessments through clinic studies and commercialization.